# Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

> **NCT02449031** · — · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 409 (actual)

## Conditions studied

- Pseudomonas Aeruginosa in Cystic Fibrosis

## Interventions

- **DRUG:** TOBI® PODHALER®
- **DRUG:** TOBI®
- **DRUG:** Bethkis®
- **DRUG:** Cayston®

## Key facts

- **NCT ID:** NCT02449031
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-05
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2022-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02449031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02449031, "Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02449031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*